CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
LY3502970 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05469126
NCT05469126Phase 1Completed

A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants

Eli Lilly and Company·interventional·Posted Jul 21, 2022·Updated May 27, 2026

In Brief

A Phase 1 clinical trial evaluating LY3502970 and Clarithromycin for Healthy. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants. This study will last up to approximately 85 days for each participant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedJul 21, 2022
Enrollment StartAug 1, 2022
Primary CompletionNov 3, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.9 years ago

Interventions

LY3502970drug

Administered orally.

Clarithromycindrug

Administered orally.